Up­dat­ed: Seagen de­pri­or­i­tizes an­ti­body-drug can­di­date from $4.2B Mer­ck deal

Seagen has de­pri­or­i­tized work on ladi­ratuzum­ab ve­dotin, the biotech qui­et­ly dis­closed in its sec­ond quar­ter fi­nan­cial re­port Wednes­day.

Seagen has been study­ing the drug in breast can­cer and oth­er sol­id tu­mors along­side Mer­ck’s block­buster check­point in­hibitor Keytru­da. In a deal worth up to $4.2 bil­lion, Mer­ck had paid $600 mil­lion up­front in 2020 for co-de­vel­op­ment and co-com­mer­cial­iza­tion rights for the an­ti­body-drug con­ju­gate, known as LV for short, as well as oth­er po­ten­tial can­di­dates that shared the same tar­get.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER